☆ 4.6 Editorial Material

Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Related references

Note: Only part of the references are listed.
Article Dermatology

Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study

W. Gulliver et al.

Summary: The study found that patients with moderate and high AN counts achieved better results at 24 and 52 weeks of treatment with adalimumab, with gender and age at onset affecting treatment effectiveness. The use of adalimumab led to a decrease in lesions, especially in inflammatory nodules, and the IHS4 scores of responders were substantially lowered. No new safety issues were detected during the treatment and observation period.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection
Article Dermatology

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

John W. Frew et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection
Article Dermatology

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

C. C. Zouboulis et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.